Professor, Pediatrics, Case Western Reserve University School of Medicine
Infectious Disease
Dr. Grace A. McComsey, MD
|
|
Give Review
Dr. Grace A. McComsey works in the field of Infectious Disease. She studied medicine at St Joseph's University Medical School. She received awards:"America's Top Doctors". Grace A. McComsey is also a published MD. She has 100 publication published. The most recent publication is: Vitamin D and bone loss in HIV. Grace McComsey accepts Medicare payments and is listed with Medicare.gov.
Publications
- Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with red...
- Vitamin D and bone loss in HIV.
- Statins to improve cardiovascular outcomes in treated HIV infection.
- Health State Utilities of Risks Associated with Antiretroviral Treatment for Human Immunodeficiency Virus (Hiv).
- Markers of renal disease and function are associated with systemic inflammation in HIV infection.
- Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.
- Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.
- Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Patients.
- Comparison of the Metabolic Effects of Ritonavir boosted Darunavir or Atazanavir versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
- Anemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy.
- Oxidized LDL levels are increased in HIV infection and may drive monocyte activation.
- Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
- Changes in metabolic syndrome status after initiation of antiretroviral therapy.
- Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.
- Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.
- Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.
- Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine ve...
- Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: the SATURN-HIV Trial.
- Vitamin D Deficiency and Altered Bone Mineral Metabolism in HIV-infected Individuals.
- Habitual nutrient intake in HIV-infected youth and associations with HIV-related factors.
- Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.
- LL-37 Concentrations and the Relationship to Vitamin D, Immune Status, and Inflammation in HIV-infected Children and Young Adults.
- Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.
- Relationships Between Inflammation, Immune Activation, and Bone Health Among HIV-Infected Adults on Stable Antiretroviral Therapy.
- Impact of randomized antiretroviral therapy initiation on glucose metabolism: AIDS clinical trials group study A5224s.
- Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.
- Rosuvastatin treatment reduces markers of monocyte activation in HIV infected subjects on antiretroviral therapy.
- C-Reactive Protein Predicts 96-Week Carotid Intima Media Thickness Progression in HIV-Infected Adults Naïve to Antiretroviral Therapy.
- Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a substudy o...
- Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation.
- Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
- Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial f...
- Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy.
- Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.
- High Prevalence of Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Pregnant Women.
- Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy-Naïve HIV-1 Infected Individuals.
- Adipokines and vascular health in treated HIV infection: an obesity paradox?
- Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.
- The Relationship between Vitamin D Status and HIV-Related Complications in HIV-infected Children and Young Adults.
- Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS ...
- Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy.
- Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
- Initiation of an Abacavir-Containing Regimen in HIV-Infected Adults Is Associated with a Smaller Decrease in Inflammation and Endothelial Activation Markers Compared t...
- Omega-3 fatty acids do not improve endothelial function in virologically-suppressed HIV-infected men: a randomized placebo-controlled trial.
- Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.
- Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s.
- Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.
- Cardiovascular Disease Risk in Pediatric HIV: The Need for Population-Specific Guidelines.
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With ...
- Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of ro...
- Bone disease in HIV infection: a practical review and recommendations for HIV care providers.
- Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.
- Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with...
- Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.
- Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat.
- Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
- Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy.
- Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults.
- Fatty liver in HIV infection: metabolic syndrome, medicines, mitochondria, and more?
- Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART.
- Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy.
- Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study.
- Osteopenia and osteoporosis in patients with HIV: a review of current concepts.
- First reported case of Neisseria meningitidis periorbital cellulitis associated with meningitis.
- Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
- New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower risk.
- Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management.
- Buffalo hump: what the experts suggest.
- Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia.
- Metabolic complications of antiretroviral therapy in children.
- High doses of riboflavin and thiamine may help in secondary prevention of hyperlactatemia.
- Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in ...
- Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lup...
- Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.
- Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.
- Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
- Effect of antioxidants on glucose metabolism and plasma lipids in HIV-infected subjects with lipoatrophy.
- Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.
- Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
- Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy.
- Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity.
- Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.
- Editorial comment: reversing lipoatrophy--better solutions needed.
- Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.
- Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects: beyond mitochondrial DNA depletion.
- Treatment options for HIV-associated central fat accumulation.
- Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled st...
- Mitochondrial dysfunction: patient monitoring and toxicity management.
- Pathogenesis and management of lipoatrophy.
- Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.
- Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
- Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.
- Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children.
- Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.
- Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.
- Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy.
- Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.
- Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
- Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
Schools
Saint Josephs University Faculty of Medicine
St Joseph Hospital and Med Center
Metrohealth Med Center
Case Western University Hosps
Doctors Specialties
- Infectious Disease Medicine
- Pediatric Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- America's Top Doctors
Education
-
Case Western Reserve University - MetroHealth -
St Joseph's University Medical School
Hospital
-
University Hospitals Case Medical Center
Drug Facts
| NPI NUMBER | 1720004336 | |
| NPPES Provider LastName | MCCOMSEY | |
| NPPES Provider FirstName | GRACE | |
| NPPES Provider ZIPCode | 44106 | |
| NPPES Provider State | OH | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 848.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 1.42 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720004336 |
| Last Name Of The Provider | MCCOMSEY |
| First Name Of The Provider | GRACE |
| View All |
Similar Doctors
|
Dr. Robert A. Bonomo, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Hanrahan, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann K. Avery, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Chmielewski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nabin K. Shrestha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Van Duin, MD |
|
|
Dr. Nazha F. Abughali, MD |
|
|
Dr. Rabin K. Shrestha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robin L. Jump, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary L. Kumar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michelle V. Lisgaris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice I. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Valsa J. Mariappuram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas D. Smith, MD |
|
|
Dr. Lucileia Teixeira Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Joseph Zachariah
This Doctor is OpenDoctor Recommended.
|